$KITE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kite Pharma, Inc.. Get notifications about new insider transactions in Kite Pharma, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 47.42 | 159,700 | 7,572,974 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 63.87 | 56,643 | 3,617,788 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 63.87 | 44,057 | 2,813,921 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 51.96 | 43,500 | 2,260,260 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 51.96 | 95,700 | 4,972,572 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 500,000 | 90,000,000 | 0 | 500 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 500,000 | 90,000,000 | 0 | 500 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 430,190 | 77,434,200 | 0 | 430.2 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 159,329 | 28,679,220 | 0 | 159.3 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 1,607,750 | 289,395,000 | 0 | 1.6 M to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 0.00 | 159,160 | 0 | 0 | 159.2 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 50,000 | 0 | 159,160 | 109.2 K to 159.2 K (+45.80 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Sell | D | 0.00 | 1,807 | 0 | 0 | 1.8 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Sell | U | 180.00 | 67,932 | 12,227,760 | 1,807 | 69.7 K to 1.8 K (-97.41 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Peacock Jonathan M | Director | Gift | G | 0.00 | 635 | 0 | 69,739 | 70.4 K to 69.7 K (-0.90 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CLARK IAN T | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CLARK IAN T | Director | Option Exercise | D | 45.95 | 17,130 | 787,124 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CLARK IAN T | Director | Sell | D | 0.00 | 5,324 | 0 | 0 | 5.3 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CLARK IAN T | Director | Sell | U | 180.00 | 1,776 | 319,680 | 5,324 | 7.1 K to 5.3 K (-25.01 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 2,632 | 0 | 0 | 2.6 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 1,029 | 0 | 0 | 1 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 2,651 | 0 | 0 | 2.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 3,520 | 0 | 0 | 3.5 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 4,360 | 0 | 0 | 4.4 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Sell | D | 0.00 | 1,807 | 0 | 0 | 1.8 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Sell | U | 180.00 | 2,553 | 459,540 | 1,807 | 4.4 K to 1.8 K (-58.56 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Sell | D | 180.00 | 70,050 | 12,609,000 | 0 | 70.1 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kazam Joshua A | Director | Buy | J | 0.00 | 70,050 | 0 | 70,050 | 0 to 70.1 K |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | D | 56.12 | 20,000 | 1,122,400 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Sell | D | 0.00 | 1,807 | 0 | 0 | 1.8 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Sell | U | 180.00 | 4,624 | 832,320 | 1,807 | 6.4 K to 1.8 K (-71.90 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Option Exercise | D | 6.89 | 30,000 | 206,700 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | U | 180.00 | 25,065 | 4,511,700 | 0 | 25.1 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | D | 0.00 | 1,807 | 0 | 0 | 1.8 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | DOUMANI ROY | Director | Sell | U | 180.00 | 150,620 | 27,111,600 | 1,807 | 152.4 K to 1.8 K (-98.81 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Sell | D | 0.00 | 2,408,084 | 0 | 0 | 2.4 M to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BONDERMAN DAVID | Director | Sell | D | 0.00 | 4,360 | 0 | 0 | 4.4 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Option Exercise | D | 0.70 | 200,000 | 140,000 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Sell | D | 0.00 | 205,586 | 0 | 0 | 205.6 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Ruchefsky Steven B | Director | Gift | G | 0.00 | 2,250 | 0 | 205,586 | 207.8 K to 205.6 K (-1.08 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | D | 0.00 | 1,807 | 0 | 0 | 1.8 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Sell | U | 180.00 | 61,467 | 11,064,060 | 1,807 | 63.3 K to 1.8 K (-97.14 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | CHAMPSI FARAH | Director | Gift | G | 0.00 | 2,800 | 0 | 63,274 | 66.1 K to 63.3 K (-4.24 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | D | 83.89 | 17,130 | 1,437,036 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | D | 55.09 | 30,000 | 1,652,700 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Option Exercise | D | 6.89 | 10,000 | 68,900 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Sell | D | 0.00 | 5,715 | 0 | 0 | 5.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Sell | U | 180.00 | 58,535 | 10,536,300 | 5,715 | 64.3 K to 5.7 K (-91.11 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | WITTE OWEN N. | Director | Gift | G | 0.00 | 12,000 | 0 | 64,250 | 76.3 K to 64.3 K (-15.74 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | D | 46.09 | 30,700 | 1,414,963 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | D | 44.91 | 96,875 | 4,350,656 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Option Exercise | D | 44.91 | 124,125 | 5,574,454 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | D | 0.00 | 41,734 | 0 | 0 | 41.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | U | 180.00 | 3,927 | 706,860 | 41,734 | 45.7 K to 41.7 K (-8.60 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Option Exercise | D | 46.09 | 38,500 | 1,774,465 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Option Exercise | D | 63.87 | 67,000 | 4,279,290 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Option Exercise | D | 63.87 | 93,000 | 5,939,910 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Sell | D | 0.00 | 39,933 | 0 | 0 | 39.9 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Sell | U | 180.00 | 16,135 | 2,904,300 | 39,933 | 56.1 K to 39.9 K (-28.78 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Gift | G | 0.00 | 5,000 | 0 | 56,068 | 61.1 K to 56.1 K (-8.19 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 46.09 | 38,500 | 1,774,465 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 63.87 | 14,850 | 948,470 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 63.87 | 11,550 | 737,699 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 51.96 | 5,031 | 261,411 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 51.96 | 11,069 | 575,145 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 6.89 | 29,167 | 200,961 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Option Exercise | D | 6.89 | 28,833 | 198,659 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | D | 0.00 | 11,150 | 0 | 0 | 11.2 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | U | 180.00 | 14,674 | 2,641,320 | 11,150 | 25.8 K to 11.2 K (-56.82 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 46.09 | 38,500 | 1,774,465 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 63.87 | 18,562 | 1,185,555 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 63.87 | 14,438 | 922,155 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 51.43 | 35,000 | 1,800,050 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 51.43 | 2,499 | 128,524 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 53.90 | 52,500 | 2,829,750 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Option Exercise | D | 53.90 | 3,752 | 202,233 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | D | 0.00 | 17,500 | 0 | 0 | 17.5 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | U | 180.00 | 4,193 | 754,740 | 17,500 | 21.7 K to 17.5 K (-19.33 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Option Exercise | D | 46.09 | 24,200 | 1,115,378 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Option Exercise | D | 45.04 | 83,334 | 3,753,363 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Option Exercise | D | 45.04 | 41,666 | 1,876,637 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Sell | D | 180.00 | 3,000 | 540,000 | 0 | 3 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Sell | D | 0.00 | 9,462 | 0 | 0 | 9.5 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 46.09 | 90,600 | 4,175,754 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 63.87 | 37,181 | 2,374,750 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 63.87 | 28,919 | 1,847,057 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 51.96 | 23,437 | 1,217,787 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 51.96 | 51,563 | 2,679,213 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 6.89 | 56,250 | 387,563 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 6.89 | 116,750 | 804,408 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | D | 0.00 | 38,675 | 0 | 0 | 38.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | U | 180.00 | 16,605 | 2,988,900 | 38,675 | 55.3 K to 38.7 K (-30.04 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 570 | 0 | 55,280 | 55.9 K to 55.3 K (-1.02 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 157 | 0 | 55,850 | 56 K to 55.9 K (-0.28 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 1,041 | 0 | 56,007 | 57 K to 56 K (-1.82 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 375 | 0 | 57,048 | 57.4 K to 57 K (-0.65 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 46.09 | 90,600 | 4,175,754 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 63.87 | 37,181 | 2,374,750 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 63.87 | 28,919 | 1,847,057 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 51.96 | 23,437 | 1,217,787 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 51.96 | 51,563 | 2,679,213 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 17.00 | 28,034 | 476,578 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 17.00 | 121,477 | 2,065,109 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 1.35 | 36,284 | 48,983 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Option Exercise | D | 1.35 | 44,110 | 59,549 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Sell | D | 0.00 | 93,667 | 0 | 0 | 93.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | Chief Operating Off ... | Gift | G | 0.00 | 27,900 | 0 | 93,667 | 121.6 K to 93.7 K (-22.95 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Sell | S | 179.66 | 4,203 | 755,127 | 61,068 | 65.3 K to 61.1 K (-6.44 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Tomasello Shawn | Chief Commercial Of ... | Grant | A | 0.00 | 4,500 | 0 | 65,271 | 60.8 K to 65.3 K (+7.40 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Sell | S | 179.66 | 3,171 | 569,714 | 21,693 | 24.9 K to 21.7 K (-12.75 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Kim Helen Susan | EVP, Business Devel ... | Grant | A | 0.00 | 6,000 | 0 | 24,864 | 18.9 K to 24.9 K (+31.81 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 179.66 | 4,228 | 759,619 | 45,661 | 49.9 K to 45.7 K (-8.47 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Grant | A | 0.00 | 8,000 | 0 | 49,889 | 41.9 K to 49.9 K (+19.10 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | MOORE TIMOTHY L. | EVP, Technical Oper ... | Sell | S | 83.31 | 7,511 | 625,741 | 41,889 | 49.4 K to 41.9 K (-15.20 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Sell | S | 179.66 | 5,283 | 949,164 | 25,824 | 31.1 K to 25.8 K (-16.98 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | SVP Clinical Develo ... | Grant | A | 0.00 | 10,000 | 0 | 31,107 | 21.1 K to 31.1 K (+47.38 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 179.66 | 7,927 | 1,424,196 | 57,423 | 65.4 K to 57.4 K (-12.13 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Grant | A | 0.00 | 15,000 | 0 | 65,350 | 50.4 K to 65.4 K (+29.79 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Sell | S | 179.66 | 948 | 170,321 | 9,462 | 10.4 K to 9.5 K (-9.11 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | JENKINSON PAUL L | Chief Financial Off ... | Grant | A | 0.00 | 2,500 | 0 | 10,410 | 7.9 K to 10.4 K (+31.61 %) |